We have recently featured a piece titled 10 Major Players With Significant Gains; 6 Reach All-Time Highs. Among the leading performers on Thursday was Akero Therapeutics, Inc. (NASDAQ:AKRO).
On Thursday, Akero Therapeutics experienced a remarkable surge, with its stock price rising by 16.33% to conclude at $54.08 following the announcement of a merger with Novo Nordisk valued at $5.2 billion.
According to a statement from Akero Therapeutics, Inc. (NASDAQ:AKRO), the two firms have entered into a definitive agreement, whereby Novo Nordisk will acquire all AKRO shares at a price of $54 per share, in addition to a non-transferable contingent value right (CVR) linked to the achievement of a specific milestone.
Every shareholder will be eligible to receive $6 in cash upon the full approval of efruxifermin by US regulatory authorities, expected by June 30, 2031, as a potential treatment for compensated cirrhosis arising from MASH.
Akero Therapeutics, Inc. (NASDAQ:AKRO) highlighted that the acquisition offer represents a 19% premium on its 30-day volume-weighted average price (VWAP) and a 42% premium compared to its closing price on May 19, right before market speculations began.
Akero Therapeutics, Inc.’s (NASDAQ:AKRO) EFX program, aimed at developing solutions for MASH, is expected to complement Novo Nordisk’s expertise in GLP-1-based metabolic therapeutics.
While we recognize the investment potential in AKRO, we believe that some AI stocks present greater opportunities for higher returns with reduced downside risk. For those interested in discovering an exceptionally undervalued AI stock that stands to benefit significantly from Trump tariffs and onshoring, check out our free report on the top short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published at Insider Monkey.
